Zimbabwe has rejected a significant American healthcare agreement worth $367m (272 million pounds) over five years because of the United States' request for confidential data.
The decision came to light after a government memo from December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "lopsided".
An official representative has since stated that the United States was seeking biological samples for scientific study and commercial purposes while was unwilling to guarantee the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further dialogue to find a deal acceptable to all parties so the nation's vital HIV treatment initiative can proceed.
Broader Implications
This rejection follows a comparable situation in Kenya, where a court halted a related deal with the US following legal challenges were raised about the safety of citizens' health data.
Since resuming office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost openness and responsibility.
Based on reports, Sixteen African countries have so far signed these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, without any equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"In essence, our nation would supply the basic resources for medical research without any assurance that the end products would be accessible to our citizens if a new pandemic arise."
Sovereignty and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were disrupting structures previously established through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage future global health emergencies.
"This mechanism is intended to guarantee that when a nation provides its information, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," he added.
"We welcome further discussions with our American counterparts on how future collaboration might be structured in a manner that honours the independence and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but suggested that talks should continue given that a large portion of the nation's HIV programmes were funded by foreign aid.
"Where specific concerns arise, including those involving information security or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," the group added.
The halted deal underscores the continuing tensions between accepting much-needed foreign assistance and safeguarding local interests in an increasingly data-driven world.